

# Vermont New High-Cost Drug Price Report: Duaklir - 60 Metered Doses

Report Due Date: 11/17/19

Field Name	Non-Public Indicator*	Duaklir 60 Metered Doses
Manufacturer Name		Circassia Pharmaceuticals
Drug Name		Duaklir Pressair
NDC		72124000101
Date Introduced to the market		10/17/2019
Introductory WAC		995
Marketing/Pricing plan description	X	<p>Marketing to support the launch of Duaklir will focus on educating HCPs and patients on the approved indication as well as safety information, all included within the FDA approved label. This education will occur in the form of: the Duaklir website, interactive core visual aids, banner ads, email promotions and HCP and patient leave-behind materials.</p> <p>Pricing is evaluated by Circassia's Pricing Committee and approved by its Board of Directors.</p>
Estimated Number of Patients who may be prescribed (US)		The US population of patients diagnosed with COPD who are treated with medication is ~15 million.
Was the drug granted breakthrough therapy designation or priority review by the FDA?		No
Date of acquisition if drug not developed by the manufacturer	X	6/17/2019
Price of acquisition if drug not developed by the manufacturer	X	*
Price of acquisition comment:		The final acquisition price was cumulative to include the acquisition of multiple products and the amount attributable to Duaklir has not been made public.

\*Information provided can be limited to what is in the public domain or otherwise publicly available; companies will need to attest that any data elements not provided are not currently in the public domain